RAF kinase (RAF)

Pan‑RAF refers to inhibitors that target all three members of the RAF kinase family—A‑Raf, B‑Raf, and C‑Raf—which are serine/threonine protein kinases involved in the RAS–RAF–MEK–ERK signal transduction cascade. This pathway is critical for regulating cell division, differentiation, and survival. Aberrant activation of this cascade—often through mutations or fusions involving BRAF—is a key driver in various cancers. Pan‑RAF inhibitors are designed to overcome limitations seen with earlier generation selective BRAF inhibitors by preventing paradoxical activation and targeting a broader range of oncogenic drivers within this family. These agents are under clinical investigation for several cancers including pediatric low-grade gliomas and melanomas[1][2][4][5].

Other names

Rapidly Accelerated Fibrosarcoma kinaseA-RafB-RafC-RafRaf-1 proto-oncogene serine/threonine-protein kinase (c-Raf)

Inhibition of all three RAF isoforms (A-Raf, B-Raf—including mutant forms—and C-Raf), blocking the RAS–RAF–MEK–ERK/MAPK signaling pathway to suppress tumor cell growth and survival[2][5][6].